Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes is a research paper published in Frontiers in Immunology (2020). On theSindex it has a DataRank of 0.756. It has been cited 153 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.756
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →FWCI
12.29
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction
Additional file 1 of Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction
Additional file 1 of Interaction, immune infiltration characteristics and prognostic modeling of efferocytosis-related subtypes in glioblastoma
Additional file 1 of Interaction, immune infiltration characteristics and prognostic modeling of efferocytosis-related subtypes in glioblastoma
Additional file 6 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 6 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 3 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 4 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 2 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 3 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 2 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 5 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 5 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 4 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 1 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 1 of Leveraging a disulfidptosis‑related lncRNAs signature for predicting the prognosis and immunotherapy of glioma
Additional file 12 of Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma
Additional file 13 of Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma
Additional file 15 of Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma
Additional file 14 of Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma